Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Osteosarcoma 1Neoplasm Metastasis 1Carcinoma 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × pepinemab × Clear all
NCT04815720 2025-01-08

KEYNOTE-B84

Vaccinex Inc.

Phase 1/2 Completed
49 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

NCT03320330 2024-07-15

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Children's Oncology Group

Phase 1/2 Completed
26 enrolled 20 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡